Altimmune to Present at Two Upcoming Virtual Investor Conferences

October 15, 2020 at 7:00 AM EDT

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:

  • H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference
    Tuesday, October 20, 20201:30 pm EDT
  • B. Riley Securities – Liver Disease Symposium
    Thursday, October 29, 2020

The H.C. Wainwright HBV presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at under Events / Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit

Investor Contacts:

Stacey Jurchison Ashley R. Robinson
Altimmune, Investor Relations LifeSci Advisors, LLC
Phone: 410-474-8200 617-430-7577

Altimmune Logo.png

Source: Altimmune, Inc.


Investor Contacts

Stacey Jurchison


Ashley Robinson
LifeSci Advisors, LLC



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail